1. Home
  2. NCPL vs ERNA Comparison

NCPL vs ERNA Comparison

Compare NCPL & ERNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

NCPL

Netcapital Inc.

HOLD

Current Price

$0.70

Market Cap

7.1M

Sector

Finance

ML Signal

HOLD

Logo Eterna Therapeutics Inc.

ERNA

Eterna Therapeutics Inc.

HOLD

Current Price

$5.95

Market Cap

7.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NCPL
ERNA
Founded
1984
2018
Country
United States
United States
Employees
20
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.1M
7.2M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
NCPL
ERNA
Price
$0.70
$5.95
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
7.4M
51.2K
Earning Date
03-19-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
31.29
EPS
N/A
N/A
Revenue
N/A
$582,000.00
Revenue This Year
$739.37
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.31
$0.13
52 Week High
$8.75
$15.88

Technical Indicators

Market Signals
Indicator
NCPL
ERNA
Relative Strength Index (RSI) 46.11 42.67
Support Level $0.59 $0.23
Resistance Level $0.84 $15.88
Average True Range (ATR) 0.13 0.82
MACD -0.06 -0.52
Stochastic Oscillator 13.35 11.75

Price Performance

Historical Comparison
NCPL
ERNA

About NCPL Netcapital Inc.

Netcapital Inc is a financial technology company. The company facilitates the growth of private companies by providing fundraising services and other consulting services. The company's online private investment platform connects entrepreneurs and investors, enabling companies to raise capital digitally. The Company operates in a single operating segment, which is the provision of fintech services.

About ERNA Eterna Therapeutics Inc.

Ernexa Therapeutics Inc is a preclinical-stage synthetic allogeneic iMSC therapy company developing medicines to treat various forms of cancer and other diseases with high unmet medical needs. Its main product candidate, ERNA-101, capitalizes on the intrinsic tumor-homing ability of MSCs (mesenchymal stem cells) to slip through the tumor's defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment. The firm's initial focus is to develop ERNA-101 in platinum-resistant ovarian cancer. Through another product candidate, ERNA-201, it is investigating anti-inflammatory cytokine (IL-10) secreting iMSCs in autoimmune disorders like rheumatoid arthritis. The company operates in a single reportable segment, the research and development of cellular therapies.

Share on Social Networks: